Baidu
map

ASCO-GI 2020:Bemarituzumab的II期FIGHT试验取得积极结果

2020-12-10 Allan MedSci原创

2020年11月10日,Five Prime宣布Bemarituzumab联合mFOLFOX6化疗达到了所有三个疗效终点。

生物技术公司Five Prime近日宣布,将于2021年1月15日至17日举行的ASCO胃肠癌研讨会上展示全球、随机、双盲安慰剂对照II期临床试验(FIGHT研究)的结果,该研究探索了Bemarituzumab联合mFOLFOX6化疗对成纤维细胞生长因子受体2b阳性(FGFR2b+)/非HER2阳性(非HER2 +)晚期胃和胃食管交界处(GEJ)癌症患者的有效性。

2020年11月10日,Five Prime宣布Bemarituzumab联合mFOLFOX6化疗达到了所有三个疗效终点,与mFOLFOX6化疗相比,联合治疗组患者的无进展生存期、总体生存率和客观缓解率得到显著改善。

Bemarituzumab是针对FGFR2b+肿瘤的首个也是唯一的研究性疗法。在大约30%的非HER2 +胃癌和GEJ癌症中,FGFR2b过表达。对于这些患者,在过去的十年中没有新的一线疗法被批准,全身化疗仍然是标准疗法。Five Prime和Roche诊断人员还发现FGFR2b在许多其他癌症中过表达,包括鳞状非小细胞肺癌、三阴性乳腺癌卵巢癌胰腺癌和肝内胆管癌。这代表了Bemarituzumab在胃癌和GEJ癌症以外潜在治疗领域。

 

原始出处:

https://www.firstwordpharma.com/node/1782054?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912498, encodeId=63d0191249895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Aug 07 01:14:23 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Nov 24 13:14:23 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378630, encodeId=0c2b13e863041, content=<a href='/topic/show?id=56fc333528' target=_blank style='color:#2F92EE;'>#Bemarituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3335, encryptionId=56fc333528, topicName=Bemarituzumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907179, encodeId=d86c90e179d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Dec 11 22:48:37 CST 2020, time=2020-12-11, status=1, ipAttribution=)]
    2021-08-07 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912498, encodeId=63d0191249895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Aug 07 01:14:23 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Nov 24 13:14:23 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378630, encodeId=0c2b13e863041, content=<a href='/topic/show?id=56fc333528' target=_blank style='color:#2F92EE;'>#Bemarituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3335, encryptionId=56fc333528, topicName=Bemarituzumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907179, encodeId=d86c90e179d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Dec 11 22:48:37 CST 2020, time=2020-12-11, status=1, ipAttribution=)]
    2021-11-24 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912498, encodeId=63d0191249895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Aug 07 01:14:23 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Nov 24 13:14:23 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378630, encodeId=0c2b13e863041, content=<a href='/topic/show?id=56fc333528' target=_blank style='color:#2F92EE;'>#Bemarituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3335, encryptionId=56fc333528, topicName=Bemarituzumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907179, encodeId=d86c90e179d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Dec 11 22:48:37 CST 2020, time=2020-12-11, status=1, ipAttribution=)]
    2020-12-12 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912498, encodeId=63d0191249895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Aug 07 01:14:23 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Nov 24 13:14:23 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378630, encodeId=0c2b13e863041, content=<a href='/topic/show?id=56fc333528' target=_blank style='color:#2F92EE;'>#Bemarituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3335, encryptionId=56fc333528, topicName=Bemarituzumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907179, encodeId=d86c90e179d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Dec 11 22:48:37 CST 2020, time=2020-12-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912498, encodeId=63d0191249895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Aug 07 01:14:23 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Nov 24 13:14:23 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378630, encodeId=0c2b13e863041, content=<a href='/topic/show?id=56fc333528' target=_blank style='color:#2F92EE;'>#Bemarituzumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3335, encryptionId=56fc333528, topicName=Bemarituzumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sat Dec 12 00:14:23 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907179, encodeId=d86c90e179d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Fri Dec 11 22:48:37 CST 2020, time=2020-12-11, status=1, ipAttribution=)]
    2020-12-11 ms3000000546723755

    学习了

    0

相关资讯

Journal of Clinical Oncology:Bemarituzumab治疗晚期胃食管腺癌的I期研究

Five Prime Therapeutics今日宣布,Bemarituzumab治疗晚期实体瘤和胃食管腺癌(GEA)患者的I期临床研究和扩展研究结果将在《临床肿瘤学杂志》的数字版中发表。

Molecular Cell:癌症生长转移新机制

来自哥本哈根大学的研究人员获得了对于癌细胞生长和转移极为重要的一些分子机制更深入的认识。他们的研究目的旨在研发出改良的、更具靶向性的药物。这些研究结果发表在近期的《分子细胞》(Molecular Cell)杂志上。 研究人员正不断地努力了解更多有关人体高等通讯过程的知识。作为细胞中的一种信号交换器,受体将一些特异的信号蛋白与特定的细胞功能连接起来。利用最先进的技术,哥

拓展阅读

对话大咖|陈凛教授:机器人手术与AI,未来外科医生的辅助还是替代?

【医悦汇】特别邀请到北京大学国际医院陈凛教授做客对话大咖,就胃癌外科治疗的最新进展进行了深度的对话。

优化现有方案PFS延长约3个月,疾病控制率85%!《柳叶刀》子刊:或为晚期胃癌患者带来新选择

该研究展示出紫杉醇联合雷莫西尤单抗作为一线转换维持方案的疗效和安全性,这种转换维持策略或可作为一种潜在的治疗选择。

ACS Nano:暨南大学韩方海等团队制备肿瘤可追踪和酶可激活的近红外荧光纳米探针对胃癌淋巴转移进行时空定位

该研究报道了具有可激活光输出的转移性LN报告基因(MLR),用于胃癌淋巴转移的精确时空定位。

Sci Rep:血清尿酸水平与胃癌发病风险的因果关系

癌症是全球一项重大公共卫生挑战。胃癌是一种常见的恶性肿瘤,在全球肿瘤死亡率中排名第四。没有发现任何证据表明遗传预测的SUA水平与胃癌风险之间存在因果关系。

NEJM:可切除胃癌的术前放化疗

与单纯围手术期化疗相比,虽然术前放化疗加用使达到病理学完全缓解的患者百分比翻倍,并且使肿瘤降期的患者百分比更高,但这些改善并未转化为总生存期或无进展生存期的改善。

中山大学黄佳国课题组ACS Nano:肿瘤追踪与酶激活型近红外荧光纳米探针用于时空可视化胃癌淋巴转移

中山大学黄佳国教授团队与广东省第二人民医院韩方海教授团队共同开发了具有高特异性和灵敏度的酶激活型近红外荧光纳米探针用于绘制GC转移淋巴结时空图的实时示踪,辅助外科精准治疗。

Baidu
map
Baidu
map
Baidu
map